OTVR

Results from New Study of Real-World Evidence Showing People with Type 2 Diabetes Achieved Clinically Significant Improved Glycemic Control with One to Two Blood Glucose Checks Per Day Using a Smart Blood Glucose Meter and Mobile App Published in Diabetes

Retrieved on: 
Thursday, May 18, 2023
Real-World Evidence, LifeScan, DTT, Diabetes, Glucose, Research, OTR, OTVR, Blood, Data, Global Medical Device Nomenclature, Ageing, Therapy, Abbreviation, Anonymous social media, Medical device, Safety

MALVERN, Pa., May 18, 2023 /PRNewswire/ -- LifeScan, a world leader in blood glucose monitoring, today announced that results from the study of real-world evidence Sustained Improvements in Readings In-Range Using an Advanced Bluetooth® Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from more than 55,000 People with Diabetes have been published in the peer-reviewed journal Diabetes Therapy.  A smaller subset of these results was first published in the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) in June, 2022. This new analysis focuses on changes over 180 days given that sustained outcomes for people with diabetes are more clinically relevant.

Key Points: 
  • A smaller subset of these results was first published in the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) in June, 2022.
  • This new analysis focuses on changes over 180 days given that sustained outcomes for people with diabetes are more clinically relevant.
  • These findings warrant further research about how age and the degree of engagement with a smart blood glucose meter and mobile app affect glycemic outcomes.
  • Abbreviations: PwT1D, people with type 1 diabetes; PwT2D, people with type 2 diabetes.